Pleomorphic xanthoastrocytoma (PXA) is a rare localized glioma characterized by frequent BRAF V600E mutation and CDKN2A/B deletion. We explored the association of copynumber variants (CNVs) with BRAF mutations, tumor grade, and patient survival in a cohort of 41 PXA patients using OncoScan chromosomal microarray. Primary resection specimens were available in 38 cases, including 24 PXA and 14 anaplastic PXA (A-PXA), 23 BRAF V600E mutant tumors (61%). CNVs were identified in all cases and most frequently involved chromosome 9 with homozygous CDKN2A/B deletion (n 5 33, 87%), a higher proportion than previously detected by comparative genomic hybridization
INTRODUCTION
Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumor predominantly affecting children and young adults. PXA has a relatively favorable prognosis compared with infiltrating astrocytomas with 5-year recurrence-free and overall survival of 70.9% and 90.4%, respectively (10) . In approximately one-third of cases, PXA demonstrates increased mitotic activity (5 mitoses per 10 high power fields [HPF] ) and/or necrosis, findings which are associated with more aggressive behavior and decreased 5-year overall survival (57.1%) (14) . As such, the 2016 WHO Classification of Tumours of the Central Nervous System has recognized anaplastic PXA (A-PXA) as a distinct entity, defined by the presence of 5 mitoses/10 HPF and designated WHO grade III (9) . Anaplasia may be focal in a tumor and manifest at first diagnosis or at time of recurrence (9) .
PXA is known to harbor a high rate of BRAF V600E mutation (up to 60%-78%) (10) while the IDH mutations characteristic of adult-type infiltrating gliomas are absent. BRAF V600E is not specific to PXA and has been identified in a number of CNS tumors, including ganglioglioma, pilocytic astrocytoma (35) , and epithelioid glioblastoma (21) . The genetic alterations underlying PXA negative for BRAF V600E are not well characterized. Whole genome (39) or exome (2) sequencing of seven PXA negative for BRAF V600E demonstrated alterations in other known cancer drivers, including mutations of TSC2 and NF1 (2) and ETV6-NTRK3 fusion (39) . Fusions of NRF1-BRAF and ATG7-RAF were also identified in two anaplastic PXA using a targeted next-generation sequencing panel (27) . The KIAA1549-BRAF fusion characteristic of pilocytic astrocytoma has not been identified in PXA (11) . Mutations of TP53 are also rare in PXA, present in approximately 6% of tumors (10) .
PXA is characterized by complex copy number variants (CNVs). Traditional cytogenetic studies have demonstrated complex karyotypes, with frequent polyploidy, multiple subclones, and complex translocations (17, 29, 32, 33, 38) . A single large series of 50 PXA analyzed by comparative genomic hybridization (CGH) demonstrated frequent whole or partial loss of chromosome 9, present in 25 cases (50%) with homozygous deletion of 9p21.3 encompassing CDKN2A/B identified in 6 of 10 cases further analyzed by array CGH (37) . Recurrent gains of chromosome 7 have also been identified in multiple studies (8, 17, 29, 37, 38) . The association of CNVs to BRAF V600E, anaplastic histology, and clinical outcomes remain to be fully elucidated.
To more fully explore these associations, we analyzed CNVs in a cohort of 41 PXA patients, 38 at primary diagnosis and 3 at recurrence only, using OncoScan chromosomal microarray and describe the association of CNVs with BRAF mutations, tumor grade and patient survival. We further characterized distinct histologic patterns of anaplasia and CNVs in 10 PXA cases showing separate areas of low-and high-grade morphology (n52) or in which matched primary and recurrent tumors (n 5 8) were available.
METHODS

Case selection and pathologic review
All studies were conducted according to Mayo Clinic and Johns Hopkins Institutional Review Board-approved protocols. The series includes 41 patients with primary diagnosis of PXA or A-PXA. The majority of cases (n 5 35) were selected from our previous series (14) based on the availability of histologic material. An additional six cases were identified from the surgical and consultation files of Mayo Clinic. These included two patients who underwent resection of primary and/or recurrent tumors at Mayo Clinic since 2013 and two consultation cases with diagnoses of A-PXA with a high-grade epithelioid component. One patient (case 6) presented with multiple neurofibromas and multiple bilateral brain tumors, including one pilocytic astrocytoma and three PXA. Genetic testing for NF1 mutation was negative. In this patient, microarray was performed on one PXA specimen and two matched recurrences.
Diagnostic slides for all specimens were reviewed by two neuropathologists (CG and RAV). A-PXA was defined according to 2016 WHO criteria by the presence of 5 or more mitoses per 10 HPF (9).
BRAF V600E and SMARCB1 immunohistochemistry
BRAF V600E mutation status was assessed as previously described (14) by immunohistochemistry (mouse anti-BRAF V600E, clone VE1; 1/100; Spring Bioscience, Pleasanton, CA, USA) and/or allele-specific PCR with fragment analysis. In the four A-PXA with epithelioid morphology, immunohistochemistry for SMARCB1 (INI-1) was performed (mouse anti-BAF47, clone 25; 1:100; BD Biosciences, San Jose, CA, USA).
DNA extraction
Sufficient histologic material was available from the primary tumor resection in 38 cases. In three cases, material was available only at tumor recurrence. Two primary A-PXA showed distinct low-and high-grade areas; DNA was extracted from each area and analyzed separately. Matched primary and recurrent tumors were examined in seven cases. One case included both matched low-and highgrade areas and tumor recurrence.
DNA was extracted from 5-micron sections of formalin-fixed paraffin embedded (FFPE) tissue using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions with slight modifications as described (15) . DNA was quantified using a Qubit fluorometer and Qubit Quant-iT dsDNA BR Assay Kit (Invitrogen, Carlsbad, CA).
Chromosomal microarray
CNV and copy neutral loss of heterozygosity (cnLOH) were detected using OncoScan assay kits (Affymetrix, Santa Clara, CA, USA). Briefly, DNA isolated from FFPE tissue was hybridized to molecular inversion probes (MIPs); gap filling utilizing the bound FFPE DNA as a template circularized MIPs; FFPE DNA was removed using an exonuclease; and the circularized MIPs were linearized, amplified, and digested prior to hybridization to oligonucleotide arrays. The arrays were scanned on a GeneChip Scanner (Affymetrix), and the images were processed with OncoScan Console Software (Affymetrix). CNV and cnLOH were identified by manual examination of the data using Chromosome Analysis Suite (Affymetrix). More detailed methods can be found on the manufacturer's website (http://www.affymetrix.com/). One primary tumor (case 34) was apparently triploid, and one tumor became tetraploid on recurrence (case 2); CNVs are shown relative to the triploid or tetraploid state. All other cases are shown relative to diploid. Copynumber changes are visualized using the Integrative Genomics Viewer (IGV, http://www.broadinstitute.org/igv).
Statistical analysis
Patient characteristics were compared between groups using the v 2 test or Kruskal-Wallis test as appropriate. Cumulative survival probabilities were estimated using the Kaplan-Meier method. The log rank test was used to compare survival across groups. In all analyses, P-values <0.05 were considered statistically significant.
RESULTS
Patient demographics
Clinical features are detailed in Table 1 and largely reflect those of our prior series (14) . At initial surgery, 24 patients (63%) were diagnosed with PXA (WHO grade II) and 14 patients (37%) with A-PXA. The median age at first diagnosis was 21 years and was similar between patients with PXA and A-PXA. While the cohort, overall, contains an equal number of male and female patients, a higher proportion of patients diagnosed with A-PXA were male (n 5 10, 71%). This was a result of selecting cases in which sufficient tissue was available for the study and does not reflect the findings of our larger clinical series in which 61% of patients with A-PXA were male (14) . The vast majority of tumors (37/38; 97%) were supratentorial with a single cerebellar PXA. BRAF V600E mutation was present in 23 cases (61%), including a comparable percentage of PXA (n 5 15, 63%) and A-PXA (n 5 8, 57%). Patients diagnosed with PXA were more likely to undergo grosstotal resection, while the majority of patients with A-PXA received adjuvant radiation and/or chemotherapy.
In three additional cases, histologic material was available only at tumor recurrence. These included: one tumor initially diagnosed as A-PXA in which the recurrence only showed lower-grade features (PXA grade II); one PXA which recurred following radiation therapy, and remained grade II; and one tumor which recurred with anaplastic transformation 15 years after primary diagnosis of PXA.
Morphologic patterns of anaplasia
Each of the A-PXA in our series showed classic diagnostic features of PXA, including pleomorphic multinucleated cells, spindle and lipidized cells, and eosinophilic granular bodies. Most commonly, primary A-PXA (10 of 14; 71%) showed either classic PXA morphology with increased mitotic activity (n 5 8) ( Figure 1A -C) or appeared somewhat more monotonous than typical PXA, with smaller tumor cells (n 5 2). Similar morphology was also noted in five recurrent A-PXA. In a subset of A-PXA, additional distinct histologic patterns were identified, including areas of small-cell, fibrillary, or epithelioid morphology ( Figure 1D -L). These patterns were present either focally within the primary tumor (n 5 4 of 14) or at tumor recurrence (n 5 4 of 9). Distinct areas of high-grade small cell morphology were identified in one primary and one recurrent A-PXA ( Figure 1D 
Copy number variants in PXA and A-PXA
CNVs were identified in all (100%) of the 38 primary and 3 recurrent tumors analyzed by OncoScan chromosomal microarray (Figure 3) . The most common alteration was homozygous deletion at 9p21.3 encompassing CDKN2A/B, which was identified in 33 of 38 (87%) primary ( Figure 3B ) and 3 of 3 (100%) recurrent tumors (Supporting Information Figure S1 ). CDKN2A/B deletion was identified in conjunction with other abnormalities of chromosome 9, most commonly whole chromosome loss (n 5 11), whole or partial loss of 9p (n 5 6), or copy-neutral loss of heterozygosity (cnLOH) (n 5 9). CDKN2A/B deletion was present in both PXA (83%) and A-PXA (93%) ( Table 2) as well as BRAF V600E mutant (87%) and wild-type (87%) tumors (Supporting Information Table S1 ). In five tumors (all PXA), loss on chromosome 9 was the sole CNV identified ( Figure 3A) .
Additional whole chromosome gains, losses, and cnLOH were frequent with many present as mosaic and subclonal abnormalities ( Figure 3A) . The most common gains (Table 2 ) included 17 (n 5 15), 12 (n 5 11), 15 (n 5 10), 121 (n 5 10), 120 (n 5 9), 112 (n 5 8), and 115 (n 5 8). We did not observe a significant association between whole chromosome gains and tumor grade. With respect to BRAF mutation status, gains of 112 (P 5 0.03) and 121 (P 5 0.009) were significantly more common in BRAF mutant tumors (Supporting Information Table S1 ). Whole arm/whole chromosome cnLOH was also frequent, identified in 14 cases. In addition to chromosome 9, recurrent whole chromosome loss or cnLOH most commonly involved chromosomes 22 (n 5 13), 14 (n 5 10), 13 (n 5 9), and 10 (n 5 6). Loss/cnLOH of chromosomes 14 (P 5 0.03) and 22 (P 5 0.009) were significantly associated with anaplastic grade (Table 2) . Adult and pediatric patients showed Figure S2 ), with no significant differences in whole chromosome gains or losses. Amplification was identified in a single A-PXA (Case 26) involving 8p and 12q. Amplifications common to infiltrating gliomas, including EGFR, PDGFRA and MET, were not present. KIAA1549-BRAF fusion was not identified. Chromothripsis was present in several tumors involving 6p and 13q (case 22), 3q (case 23), Xp (case 30), and 1p (case 37). Apart from CDKN2A/B deletion, focal CNVs were largely non-recurrent, and most did not encompass genes known to be involved in gliomagenesis. In three tumors negative for BRAF V600E, focal deletions were identified, which involved BRAF (cases 21 and 35) or RAF1 (case 22).
In three cases, tumors were analyzed only at recurrence (Supporting Information Figure S1 ). Each case demonstrated CNVs of chromosome 9 with homozygous deletion of CKDN2A/B. Additional large chromosomal gains/losses were also present in cases 39 and 40. In case 41, numerous CNVs were identified with multiple focal gains/losses. This included both deletion of ATRX at Xq13 in a male patient and deletion of 4q encompassing TENM3 (ODZ3), an alteration identified in epithelioid A-PXA and epithelioid glioblastoma (1). The tumor did not show epithelioid morphology.
Association of CNVs with patient survival
Median follow-up was 6 years (range 0 to 24) for all patients with material available from primary resection. Given the relatively small cohort size, our ability to correlate CNVs with patient survival was limited to univariate analysis. Histologic grade ( Figure 4A ) was strongly associated with overall survival, with significantly shortened survival in patients with A-PXA (P 5 0.003). Although not statistically significant, BRAF mutant tumors had longer overall survival ( Figure 4B ) (P 5 0.10). We did not observe a significant association with homozygous deletion of CDKN2A/B ( Figure 4C ) and overall survival (P 5 0.78), although CDKN2A/B deletion was present in all but five tumors in our series. While loss/cnLOH of chromosomes 14 and 22 were 
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Vaubel et al more common in A-PXA (Table 2) , we did not observe an association of chromosome 14 ( Figure 4E ; P 5 0.11) or chromosome 22 loss ( Figure 4F ; P 5 0.45) with survival. Similarly, we did not observe an association of chromosome 7 gain with overall survival (P 5 0.38, not shown). Of the 33 tumors with CDKN2A/B deletion, tumors with multiple additional CNVs had shortened Figure 4D ; P 5 0.083), but this was not statistically significant.
CNVs in primary and recurrent PXA
In 10 cases, matched specimens were analyzed by OncoScan, including 2 primary A-PXA with distinct areas of low-and highgrade morphology, 7 cases with matched primary and recurrent tumors, and 1 case with both matched primary low-/high-grade areas and tumor recurrence ( Figure 5 ). Following initial surgical resection, one patient (case 27) received radiation and temozolomide, one received only radiation (case 2), while 4 patients (cases 6, 11, 12, and 22) received no adjuvant treatment. In two patients (case 20 and 31), treatment was unknown. While homozygous deletion of CDKN2A/B was identified in all matched samples, other copy-number changes on recurrence or anaplastic transformation were complex. Of the two cases with matched low-/high-grade areas ( Figure 5A ), in case 25, identical CNVs were present in areas of low-grade PXA and areas with mitotically active monotonous cells. In contrast, in case 30, low-grade PXA and high-grade epithelioid elements showed complex and largely distinct patterns of CNVs. In case 27 ( Figure 5B ), the primary tumor demonstrated distinct components of low-grade PXA and high-grade SMARCB1 deficient elements (Figure 2 ). While the PXA component showed only CNVs of chromosome 9, additional mosaic gains/losses were present in the high-grade areas. At recurrence, the tumor was predominantly epithelioid with similar mosaic gains/losses and additional losses involving 8p, 14p, and 4q. Case 31 presented as A-PXA with numerous whole chromosome gains ( Figure 5C ). Intriguingly, at recurrence, the tumor showed only CNVs of chromosome 9 and homozygous deletion at Xq26.1 and Xq26.2, also present in the primary tumor. Epithelioid elements were present at recurrence but were focal and could not be analyzed independently in this case. In cases 20, 12, and 22, matched primary PXA and recurrent A-PXA showed largely similar CNVs. In case 2, only CNVs of chromosome 9 were identified in the primary tumor, while many additional gains/losses were present on recurrence and anaplastic transformation. In case 11, numerous predominantly whole chromosome gains were identified in the primary PXA. At recurrence, the tumor showed a small cell pattern ( Figure 1D-F) and additional superimposed focal gains and losses ( Figure 5C ), which included a new homozygous deletion at Xq13 involving ATRX. In case 6, the tumor recurred as PXA and showed new mosaic gains on chromosomes 5, 7, 8, 18, and 22. At second recurrence, these gains were absent, while additional losses on 11q and 18 were identified, and the tumor was indistinguishable from fibrillary glioblastoma ( Figure 1G-I ).
DISCUSSION
The most striking features of our series are the overall frequency of CNVs in PXA and the presence of CDKN2A/B homozygous deletion in the overwhelming majority (33/38; 87%) of cases ( Figure  3) . CDKN2A encodes the p16 INK4A tumor suppressor, a central regulator of cell cycle progression. Inactivation of p16 is a common finding in a wide variety of malignancies (30) , including a high proportion of IDH-wild-type infiltrating gliomas (3). Loss of p16 has been shown to be associated with adverse outcomes in BRAF mutant pediatric low-grade gliomas (12) and identified in BRAF mutant pediatric high-grade astrocytomas (34) and secondary highgrade gliomas (23) . However, in our series, CDKN2A/B deletion was not associated with tumor grade or the presence of BRAF V600E (Table 2 and Supporting Information Table S1 ). Similarly, CDKN2A/B deletion showed no association with overall patient survival ( Figure 4C ), although our analysis is limited given the small number of cases which lacked the alteration. Rather, it appears that CDKN2A/B deletion, like BRAF V600E, is central to the underlying genetics of PXA. This finding is intriguing given the recognition that oncogenic activation of the MAPK pathway can lead to cellular senescence (5), as has been observed in models of BRAF mutant glioma, but this is abrogated by loss of p16 (13, 16, 28) . As such, the presence of CDKN2A/B deletion may underlie (29) 2 (5) 3 (13) 1 (4) 8 (57) 1 (7) 0.009* Loss 214 cnLOH 14
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the more aggressive behavior of PXA relative to other BRAF mutant low-grade gliomas.
Our findings, in many respects, reflect those of a prior large case series (37) . In 50 cases analyzed by CGH, alterations of chromosome 9 were frequent, identified in 25 cases (50%) with CDKN2A/ B deletion in 6 of 10 (60%) cases further characterized by array CGH. Other recurrent CNVs shared with our series included gains on chromosomes 7 and 20 as well as losses on 22 (37) . However, these alterations and CNVs, overall, were much more common in our series (Table 2 ). This likely reflects the increased genomic resolution of the OncoScan array relative to CGH techniques and its ability to detect cnLOH and mosaic CNVs (http://www.affymetrix. com/). In both series, amplifications typical of glioblastoma, such as EGFR, PDGFRA, and MET, were absent (37) . While one case in our series did show amplification, this involved regions of 8p and 12q, which do not contain genes known to be involved gliomagenesis.
Our ability to correlate CNVs with patient outcomes was limited in this series. While loss or cnLOH of chromosomes 14 and 22 were more common in A-PXA (Table 2) , this did not correlate with patient survival (Figure 4) . Of the variables which we examined, histologic grade was the strongest predictor of patient survival. Although not statistically significant, decreased survival was observed for patients with tumors lacking BRAF V600E, an association found to be significant in the larger clinical series (14) . A similar trend was observed in tumors with numerous CNVs. Further study is needed to determine genetic alterations associated with aggressive behavior in PXA.
On anaplastic transformation, PXA has been well-documented to show other histologic patterns, including epithelioid, fibrillary, or small cell morphology (19, 20, 36) . However, in our series, the majority of A-PXA retained the characteristic histologic features of PXA or showed smaller and more monotonous cells. In four A-PXA, focal epithelioid morphology was identified, a finding which has gained recent attention due to a possible relationship of A-PXA to epithelioid glioblastoma (7) and the identification of SMARCB1 (INI-1) loss in a subset of these tumors (4, 6, 18) . While epithelioid morphology was present in a relatively high percentage of the primary A-PXAs in our series (3/14, 21%), it should be noted that two consult cases were included specifically due the presence of epithelioid morphology, and our series may overestimate its prevalence. Intriguingly, each of the epithelioid tumors demonstrated loss of chromosome 22, which includes the SMARCB1 locus at 22q11.2 ( Figure 1A) . However, SMARCB1 expression was lost in a single tumor and was confined to the epithelioid elements (Figure 2) . Several similar cases have been reported (4, 6, 18) , and the term SMARCB1-deficient anaplastic pleomorphic xanthoastrocytoma has been suggested in the 2016 WHO Classification to describe these tumors (9) .
Recent studies have also proposed a relationship between epithelioid A-PXA and epithelioid glioblastoma, a provisional entity newly recognized in the 2016 WHO Classification (7). These tumors share overlapping histologic features and both harbor frequent BRAF V600E, which is present in approximately 50% of epithelioid glioblastoma (21) . A recent study also identified homozygous deletion of TENM3 (ODZ3) at 4q34.3 to be a shared genetic abnormality, identified by FISH in 7 of 11 epithelioid glioblastoma and 2 of 5 epithelioid A-PXA (1). In our series, focal deletion of 4q encompassing TENM3 was identified in a single recurrent A-PXA (case 41, Supporting Information Figure S1 ), which did not show epithelioid morphology. While TENM3 loss is rare in A-PXA overall, it should be noted that our analysis of epithelioid A-PXA was limited as only two of four epithelioid A-PXA had sufficient tissue available to separately analyze the epithelioid areas. The significance of TENM3 loss in A-PXA remains to be fully elucidated.
Prior studies have reported clearly defined focal CNVs leading to progression of low-grade astrocytomas (24) . In our series, the changes associated with recurrence and anaplasia were complex and variable ( Figure 5 ). Of the 10 cases with matched primary/ recurrent tumors or matched areas of low-/high-grade morphology, 4 cases showed similar CNVs on recurrence and/or anaplastic transformation. In other cases, numerous additional CNVs were identified in the high-grade areas and, as such, the specific changes contributing to aggressive behavior are unclear. The role of radiation in promoting these copy-number changes was also variable; of two patients known to receive radiation, one showed complex CNAs on recurrence (case 2) while the other patient (case 27) showed recurrence of a SMARCB1 deficient component present at initial resection. Additionally, some CNVs, predominantly large gains/losses, were lost on recurrence, suggesting a nonlinear process of clonal evolution. Upon anaplastic transformation, only three cases showed additional genetic alterations well-characterized in other CNS tumors, including the case described above with SMARCB1 loss and two recurrent tumors with focal deletion of ATRX. To our knowledge, activation of the alternative lengthening of telomeres pathway has been reported in a single A-PXA without loss of ATRX expression (31) and deletion (vs. mutation) is an uncommon mechanism of ATRX inactivation.
In summary, our study confirms CDKN2A/B homozygous deletion as a key genetic alteration in PXA, irrespective of tumor grade, BRAF mutation, or clinical outcome. The prevalence of chromosomal gains, losses, and cnLOH may be useful in diagnostically challenging cases to differentiate PXA from other low-grade gliomas and from giant cell glioblastoma, which typically lack CDKN2A/B deletion (22, 25, 26) . On anaplastic transformation of PXA, changes in both copy-number and tumor morphology are variable and complex, and further studies are needed to more fully characterize the genetic changes underlying anaplasia in PXA.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article at the publisher's web-site: Figure S1 . A. Genome wide CNVs in recurrent PXA and A-PXA. Histologic material was available only at tumor recurrence in three cases. In case 41, focal deletion of Xq13 involves ATRX. B. CNVs of chromosome 9 in recurrent tumors. All showed homozygous deletion of CDKN2A/B. Figure S2 . Genome wide copy-number variants in pediatric and adult PXA. Cases are grouped according to patient age (pediatric, age<18 or adult, age18) and tumor grade. Chromosomal gains, losses, and copy-neutral loss of heterozygosity (cnLOH) in 38 primary PXA resection specimens are visualized using the Integrative Genomics Viewer (IGV, http://www.broadinstitute. org/igv). Table S1 . Clinical characteristics and frequency of whole chromosome gains, losses, and cnLOH in BRAF V600E and wildtype tumors.
